Even before the COVID-19 outbreak, telehealth proved to be an effective and innovative way to deliver quality behavioral healthcare. AltaPointe clinicians provided more than 13,000 telehealth services in 2019. We anticipate that number to rise significantly in light of this pandemic.

MOBILE, Ala. (PRWEB)
May 08, 2020

In these unsettling times, AltaPointe Health recognizes the need to transform its core healthcare model to navigate the path ahead. We are redefining success by tackling the obstacle of timely and appropriate access to both behavioral and primary care. We continue to implement best practices while adopting new technologies and strategies to increase our focus on whole-person care.

Even before the COVID-19 outbreak, telehealth proved to be an effective and innovative way to deliver quality behavioral healthcare. It allows providers to see patients “virtually” anytime, anywhere, through the use of advanced mobile technologies. AltaPointe clinicians provided more than 13,000 telehealth services in 2019. We anticipate that number to rise significantly in light of this pandemic.*

Our data shows an increase in calls for access to care when compared to the same time period last year. Fear of the illness, economic stress, and the uncertainty of the pandemic’s duration will encourage people to seek mental health support who never needed it before. We want you to know this is not unusual, and we are here to help you and your family.

In today’s healthcare landscape, patients expect hospitals and health systems to provide high-quality care. What sets providers apart is the ability to offer a personalized patient experience. Each day AltaPointe’s leadership team and staff strive to create and sustain a “culture of quality.” We hope to exceed patient expectations, whether in person or via telehealth.

Just as our predecessors met challenges that enhanced the care they provided, we must continually face and conquer challenges, such as COVID-19, for the mental and physical well-being of people living with mental health issues, intellectual disabilities, and substance use disorders. Past experiences have proven our resilience, and collectively, we will get through this unprecedented time.

*AltaPointe provides more than 1 million services to more than 35,000 individuals each year in our residential, outpatient and psychiatric hospital settings.

Share article on social media or email:

Worldwide Business with kathy ireland® Streaming LIVE Sun. 5/10 and Weds. 5/13

Worldwide Business with kathy ireland® will be LIVE streaming this week’s episode of their successful business program on Sunday, May 10, 2020 and Wednesday, May 13, 2020 at 8:00pm ET / PT – prime time viewings on each U.S. coast!

LOS ANGELES (PRWEB)
May 08, 2020

Worldwide Business with kathy ireland® will be LIVE streaming this week’s episode of their successful business program on Sunday, May 10, 2020 and Wednesday, May 13, 2020 at 8:00pm ET / PT – prime time viewings on each U.S. coast! This episode’s exclusive interviews will spotlight key executives from Techolution and Bravado Pharmaceuticals.

As leaders in their industries, the two companies featured demonstrate the unique branding opportunity Worldwide Business with kathy ireland® offers by bringing strategic messages and unique solutions to the business community.

Company Spotlight

Techolution: Headquartered in New York City, with additional offices in India, Singapore, Indonesia, and Mauritius, the company specializes in building and implementing managed services and solutions for customers that are looking to digitally transform their business. Whether a company is at the beginning stages or further along with their digital transformation journey, Techolution’s team of IT professionals have significant expertise in the areas of cloud migration and automation, internet of things, big data, artificial intelligence, and CX/UX optimization.

Owner & CEO, Luv Tulsidas explains, “Twenty percent of businesses to date have moved their operations to the cloud. What that means is eighty percent of them have not transformed to the cloud yet. That is going to be an interesting, long journey because in order to compete in the new digital economy, companies have to stay relevant and move to the cloud. That’s step one of multiple steps to be competitive.” He expresses that the Techolution team allocates dedicated time to ensure understanding of each clients’ specific problem. In this way, they can get businesses’ computing systems where they need to be in today’s digital world to really help them succeed.

Bravado Pharmaceuticals: Headquartered in Lutz, Florida, Bravado Pharmaceuticals’ mission is to be a world-class company and to attack afflictions that many humans face, including cancer, diabetes, cardiac issues and more. The company works with each of their clients on an individual basis, and their platform offers the opportunity to complete projects more efficiently and effectively without interruption. The senior management team at Bravado Pharmaceuticals has an abundance of experience in the contract development arena, and is even led by a CEO that is a pharmaceutical development scientist with 25+ years’ experience himself.

Chairman & CEO, Brian McMillan states that Bravado Pharmaceuticals offers many advantages for big pharma companies. He explains, “The process that companies currently need to go through to develop and produce pharmaceuticals can be challenging. A lot of big pharma companies outsource to smaller companies like us because there’s not quite as much red tape, we’re quick on our feet and we can get things done much quicker. Something that might take one to two years, we can do within six months.”

To learn more about the companies highlighted above, click here on Sunday, May 10, 2020 and Wednesday, May 13, 2020 at 8:00pm ET / PT to catch their full interviews during the LIVE stream of this week’s episode of Worldwide Business with kathy ireland®!

About Worldwide Business with kathy ireland®

Worldwide Business with kathy ireland® is a weekly half-hour show featuring global executives sharing their business insights and framing the opportunities shaping their industries. Hosted by a business mogul, Kathy Ireland interviews some of the brightest minds in business today. The show broadcasts on Fox Business Network as part of their sponsored content line up and globally on Bloomberg Television. Worldwide Business with kathy ireland® extends beyond the weekly on-air program with digital content delivered on various video platforms and across social media.

Share article on social media or email:

Drs. Geof Tidey, Anish A. Shah, Erika B. Johnston-MacAnnany and Michael Edelstein of Shady Grove Fertility Richmond.

While this pandemic shook all of us to our core, what never wavered was our commitment to our patients. We’re thrilled we were able to devise safe, effective care strategies that keep our patients advancing and progressing toward their goal of building a family.

RICHMOND, Va. (PRWEB)
May 08, 2020

SGF, a pioneer in reproductive medicine, research, and innovation, announced today that SGF Richmond has resumed all fertility procedures and treatments in its Stony Point location. While its Henrico Doctors’ Hospital – Forest location is still closed temporarily, all Greater Richmond area patients may start or resume fertility care.

COVID-19 Safety Precautions

“We’ve modified the current environment with the safety of patients and care team the top priority. This means prescreening patients before they enter the building, limiting the number of patients in our waiting rooms, providing additional space throughout the facility for physical distancing, increasing our infection control protocols, wearing masks, and much more. We’re all doing our part and remain diligent to providing care in the safest environment possible,” shared Anish Shah, M.D., of SGF Richmond.

Fertility Treatments Now Available in Richmond

Comprehensive fertility services, such as fertility and ovarian reserve testing and diagnosis, semen analysis, a full range of fertility treatments such as ovulation induction and intrauterine insemination (IUI), and cycle monitoring, in vitro fertilization (IVF), donor egg, sperm, and embryo treatment, genetic screening and testing, IVF for inherited genetic disease prevention, gestational carrier, egg freezing, fertility preservation for patients with cancer, and LGBTQ family building are all currently available at SGF Richmond. Patients seeking a fertility consult with an SGF physician may do so using during a secure, private video consult.

“While this pandemic shook all of us to our core, what never wavered was our commitment to our patients. We’re thrilled we were able to devise safe, effective care strategies that keep our patients advancing and progressing toward their goal of building a family. Infertility is a disease that affects us emotionally, physically, spiritually, and often financially. It’s been inspiring to see the strength of the human spirit persevere during this time of uncertainty. Fortunately, thanks to the tremendous efforts made by frontline healthcare professionals and everyone doing their part to shelter in place for a while, the number of new cases and hospitalizations has drastically reduced across our nation. New guidance allows us to provide care for infertility as an essential service,” said Erika Johnston, M.D., of SGF Richmond.

Read more about SGF’s safety protocols.

SGF Richmond Makes Treatment Affordable

SGF Richmond offers a variety of insurance networks as well as innovative financial programs, including a 100% refund guarantee program. This exclusive program provides patients with the opportunity to pay a fixed amount for up to six fresh IVF or donor egg cycles and any subsequent frozen embryo transfers (FETs). In the event the patient does not take home a baby, SGF provides a full refund. Eighty-two percent of participants take home a baby using their own eggs and 86 percent take home a baby when using a donor egg.

SGF Richmond also offers a Shared Help Discount Program, an income-based program that offers a discount on most treatments and procedures provided by SGF Richmond, the Military Discount Program, which offers active U.S. military and reservists a discount off qualifying self-pay rates, and a Shared Donor Egg Program, which reduces the cost of donor egg treatment by up to 50 percent when sharing donating eggs with other patients—an approach that does not lower the chances of conception but does significantly lower the cost.

To learn more or to schedule a video consult with an SGF Richmond physician, call 1-888-761-1967.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 85,000 babies born and counting. With 38 locations throughout FL, GA, MD, NY, PA, VA, D.C., and Santiago, Chile, we offer patients virtual physician consults, individualized care, accept most insurance plans, and make treatment affordable through innovative financial options, including treatment guarantees. More physicians refer their patients to SGF than any other center. Call 1-888-761-1967 or visit ShadyGroveFertility.com.

Share article on social media or email:

“We are pleased to recognize Dr. Daniel Reznicek as a UroLift Center of Excellence for his commitment to providing consistent care to BPH patients using the UroLift System treatment,” said Dave Amerson

PLEASANTON, Calif. (PRWEB)
May 08, 2020

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Daniel Reznicek M.D., Pacific Northwest Urology Specialists in Bellingham, WA, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Reznicek has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“We are pleased to recognize Dr. Daniel Reznicek as a UroLift Center of Excellence for his commitment to providing consistent care to BPH patients using the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “This achievement has helped many patients experience durable, long-term relief from the burdensome symptoms of BPH while preserving sexual function*1,2.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504 nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

“Organoid Therapeutics gives patients the opportunity to regain control of their health and the ability to return to daily life,” said Richard Simon, producer for the Advancements series.

JUPITER, Fla. (PRWEB)
May 07, 2020

Scheduled to broadcast in the fall of 2020, Advancements with Ted Danson will focus on innovations in artificial organ technologies for the treatment of endocrine disorders. Check local listings for more info.

This segment will take a look at Organoid Therapeutics, Inc. (Organoid Therapeutics) and will educate about the development of its organoid-based therapies to correct hormone deficiencies and cure diseases, such as diabetes, hypothyroidism, and infertility.

Viewers will learn about Organoid Therapeutics’ portfolio of patent-pending organ engineering and tissue repair technologies, which span multidisciplinary fields, including engineering, and advanced robotics for large scale manufacturing.

“We are extremely excited to share our technology and believe it has the potential to cure diseases such as diabetes, hypothyroidism, and infertility. Our commercial product will be off-the-shelf universally compatible organoids that will replace current therapies like daily insulin injections and daily medications. We currently have proof of concept for this technology and are finalizing a prototype for preclinical and clinical evaluation. We hope viewers take interest in our cause and follow our journey to market,” said Denver Faulk, PhD, CEO & Co-founder.

Patients with chronic conditions face a number of important barriers to adequate disease management, including lack of access to medication, overly complex treatment regimens with serious side effects, increased complication and mortality rates, and disproportionate financial strain. Organoid Therapeutics’ biopharmaceutical products offer patients with end-stage glandular organ disease an alternative to a lifetime of pharmacological therapy.

“Organoid Therapeutics gives patients the opportunity to regain control of their health and the ability to return to daily life,” said Richard Simon, producer for the Advancements series. “We are excited to explore the technology and share this information with the public.”

About Organoid Therapeutics:

Organoid Therapeutics is a Pittsburgh based biotech company with a mission of using advanced robotics to mass produce off-the-shelf, universally compatible functional organs to treat patients around the world suffering from organ failure. The company believes its functional human organs will cure endocrine disorders such as diabetes, thyroid disease, and infertility. Its focus is to develop artificial organ technologies to offer patients with end stage organ disease a curative alternative to continuous maintenance therapy.

In the future, Organoid Therapeutics plans to develop other organoids to address other glandular diseases such as hypothyroidism and infertility and to offer its revolutionary treatment as universally accessible by creating organoid banks and outpatient centers where diabetes, hypothyroidism, and other glandular organ deficiencies can be treated with minimally invasive implantation of the organoids.

For more information, visit: http://www.organoidtherapeutics.co.

About Advancements and DMG Productions:

The Advancements series is an information-based educational show targeting recent advances across a number of industries and economies. Featuring state-of-the-art solutions and important issues facing today’s consumers and business professionals, Advancements focuses on cutting-edge developments, and brings this information to the public with the vision to enlighten about how technology and innovation continue to transform our world.

Backed by experts in various fields, DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming on which both viewers and networks depend.

For more information, please visit http://www.AdvancementsTV.com or call Richard Simon at 866-496-4065.

Share article on social media or email:

Cherry Bekaert Adds Seven Professionals to Partner Group

RICHMOND, Va. (PRWEB)
May 07, 2020

Cherry Bekaert LLP (“the firm”) is pleased to announce the promotions of seven professionals to the Firm’s Partner Group, effective May 1, 2020: Ryan Blankenship, CPA; Sean Carlin, CPA, CFA; Sarah Farlow, CPA; Dale Hrapchack, CPA; Adam Hunter, CPA; Jessica Simmons, CPA; and Amber Teague, CPA. Ryan, Sarah, Dale and Amber will serve as Tax Partners, Sean will serve as Advisory Partner, and Adam and Jessica will serve as Assurance Partners.

“With the addition of these seven accomplished professionals, Cherry Bekaert’s Partner Group continues to grow stronger,” said Michelle L. Thompson, Cherry Bekaert’s Chief Executive Officer and Firm Managing Partner. “They exemplify our Firm’s shared values each day and make a difference for our clients by providing valuable guidance and support in the pursuit of their business goals.”

Based in Cherry Bekaert’s Nashville, TN office, Ryan Blankenship is a Partner in the Tax Services practice. He is focused on privately-held businesses, real estate, healthcare and professional services, and serves as a member of the Firm’s Not-For-Profit Center of Excellence.

Sean Carlin is a Bethesda, MD-based Partner in Cherry Bekaert’s Transaction Advisory Services practice. His industry expertise includes the technology, restaurant, manufacturing and service-related sectors, as well as private equity. Sean advises on mergers and acquisitions, financial due diligence and quality of earnings engagements.

Sarah Farlow, based in Cherry Bekaert’s Charlotte, NC office, is a Partner in the Tax Services practice. She specializes in providing tax consulting and compliance services to multi-state and multi-national companies in the private equity, technology, life sciences and industrial industries.

Based in Cherry Bekaert’s Austin, TX office, Dale Hrapchak is a Partner in the Tax Services practice. He provides tax compliance guidance, tax savings strategies and business management consulting to the real estate, professional services, healthcare and technology industries.

Adam Hunter provides expertise to publicly-traded and private businesses in the areas of revenue recognition, business combinations, complex debt and equity transactions and SEC reporting. He is based in Cherry Bekaert’s Tampa, FL office and serves the technology, healthcare, life sciences and industrial sectors as a Partner in the Assurance Services practice.

Jessica Simmons, based in Cherry Bekaert’s Raleigh, NC office, is a Partner in the Assurance Services practice focusing on the technology, industrial/manufacturing, healthcare and life sciences industries. She addresses financial reporting and advisory needs for emerging growth companies as well as middle-market companies.

Amber Teague is a Partner in the Tax Services practice and is based in Cherry Bekaert’s Austin, TX office. She specializes in providing tax and business consulting guidance to middle-market businesses and their owners. Amber works closely with owner-managed businesses and high net worth individuals to navigate the ever-changing tax landscape through proactive tax planning, consulting and compliance.

About Cherry Bekaert

Ranked among the largest audit, tax and advisory firms in the U.S., Cherry Bekaert LLP offers specialized solutions in the areas of cybersecurity, specialty tax, transaction advisory, risk advisory, digital & technology solutions, benefits consulting, fraud & forensics, government contract consulting, valuation and wealth management. With clients in all 50 states and internationally, we have specialists in the sectors of technology, healthcare and life sciences, industrial manufacturing, private equity, real estate and construction, professional services, hospitality and retail, government and not-for-profit. We exercise a deliberate curiosity to know our clients’ industries and work collaboratively as one team to guide them forward.

Cherry Bekaert LLP is a founding, independent member of Baker Tilly International, a top-ten global accountancy and business advisory network. Visit us at cbh.com and follow us on LinkedIn, Facebook or Twitter.

Share article on social media or email:

“This relationship brings us much closer to fulfilling our mission of finding the link between patients and therapies to improve lives,” said BullFrog AI’s Founder and CEO, Vin Singh.

BALTIMORE, Md. (PRWEB)
May 07, 2020

BullFrog AI, Inc., a precision pharmaceutical company built around a powerful artificial intelligence (AI) platform, proudly announces its technology partnership with EastBanc Technologies. EastBanc Technologies will serve as a technical partner providing a world class team of AI scientists, mathematicians and software developers to enable BullFrog AI to strengthen their efforts and bring value to late stage clinical development programs in the biopharma industry.

“We are very excited about partnering with EastBanc Technologies. They have exceptional leadership and a world class team of engineers and scientists that will play important strategic and operational roles for BullFrog AI. This relationship brings us much closer to fulfilling our mission of finding the link between patients and therapies to improve lives,” said BullFrog AI’s Founder and CEO, Vin Singh. “This partnership puts us in a great position going into the launch of our extended seed round in June.”

“In these uncertain times, partnering with a leading AI provider like BullFrog AI is more critical than ever. Take the industry’s top data scientists, provide them with scientific algorithms developed by John Hopkins and the right technology and you will potentially fast track the search for vaccines or medications — this could be a game changer in times like the current COVID 19 crisis,” explained EastBanc Technologies’ CEO Philippe Lanier. “Our teams specialize in assisting customers to adopt an emerging approach to AI through automated, process-oriented data analytics that reduce insight-delivery-time and improve insight quality. Our methodology streamlines messy data pipelines and affirms the unified transparent app development and delivery processes.”

For more information on BullFrog AI, visit http://www.bullfrogai.com.

About BullFrog AI

BullFrog AI is an innovator in artificial intelligence. Its proprietary bfLEAPTM analytics engine is the only tool of its kind, designed to analyze massive, complex, multi-factorial clinical data sets. BullFrog AI’s technology is poised to revolutionize drug development, enabling researchers and clinicians to match therapies to patients, streamlining clinical trials, reducing development costs and accelerating R&D cycle time to drug approval and commercial launch. BullFrog AI has an exceptional team of life science industry leaders, AI technologists, scientists, physicians and advisors, all determined to make BullFrog AI become the undisputed leader in precision medicine.

About EastBanc Technologies

EastBanc Technologies has been working at the frontier of technology since 1999. Today, the firm provides full-lifecycle software development delivering flexible technology solutions that seamlessly integrate with existing systems—whether on premise or cloud. EastBanc Technologies partners with public and private sector clients to solve their most difficult technology challenges. Headquartered in Washington DC, the firm employs 200 people. To learn more, visit eastbanctech.com.

For more information regarding BullFrog AI, contact:

Vin Singh

Founder and CEO

Vin@Bullfrogai.com

301-367-2055

http://www.BullFrogAI.com

Baltimore, Maryland

For Media Inquiries, please contact:

Liz Thibodeau

Thibodeau Media Group

Liz@thibmedia.com

Share article on social media or email:

Angelina Sciolla named one of the 2020 PM360 ELITE 100

Sciolla is being recognized for her outstanding achievements as a communicator, brand steward and team builder at Benchworks.

PHILADELPHIA (PRWEB)
May 07, 2020

PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics and medical device sectors, has named Angelina Sciolla as one of the 2020 PM360 ELITE 100 in the Creative Director category. Now in its sixth year, the PM360 ELITE (Exceptional • Leaders • Innovators • Transformers • Entrepreneurs) represent the most influential people in the healthcare industry today.

PM360 is recognizing Sciolla for nearly two years of outstanding achievements as a communicator, brand steward and team builder at Benchworks. Since joining the agency, Sciolla has doubled the number of creative staff and introduced tools for brand building that have contributed to significant organic growth. She oversaw the agency’s rebrand, launched in early 2020, and created a smart, flexible AOR model that prioritizes value for clients, regardless of size or budget.

Thad Bench, BW Health Group CEO and founder, said, “It is no surprise to us—nor should it be a surprise to anyone who has been fortunate enough to work with her throughout her career—that Angelina is being recognized for her outstanding achievements as our Creative Director. Not only has she been a driver of creative plan, product, and campaign development and execution, her leadership continues to inspire everyone on her team and at Benchworks to exceed their own, our agency’s and clients’ expectations.”

The PM360 ELITE Awards were established in 2015 to recognize individuals who have made a significant impact on the healthcare industry throughout their careers. More than 500 submissions were received and nominees were evaluated and selected by the PM360 editorial staff based on their accomplishments; testimonials from their bosses, clients, and colleagues; and supporting evidence that reflects the impact of their efforts. A total of 100 winners were selected across 18 categories, including Creative Directors, Data Miners, Digital Crusaders, Disrupters, Drug Researchers and Developers, Entrepreneurs, Launch Experts, Leaders of the Future, Marketing Teams, Master Educators, Mentors, Patient Advocates, PR Gurus, Sales MVPs, Strategists, Talent Acquisition Leaders, Tech-know Geeks, and Transformational Leaders.

“At a time when the world is being impacted by a healthcare crisis in the COVID-19 pandemic, it is nice to be able to reflect on the extraordinary work those in the life sciences do to discover, develop, and promote life-saving treatments,” says Anna Stashower, CEO and Publisher of PM360. “Our ELITE winners epitomize the very best of our industry. We are incredibly thankful for everything they do and proud to honor all of their achievements.”

The winners were profiled in PM360’s May 2020 issue. You can read their profiles online at https://www.pm360online.com/the-2020-pm360-elite-100.

About Benchworks

A continuously evolving enterprise for over 25 years, Benchworks is a hybrid model of consultancy and brand-building creative agency. Powered by a diverse mix of agency and industry talent, Benchworks blends brand and business strategies to deliver flexible, scalable solutions that answer and anticipate the challenges of a complicated life sciences marketplace. For additional information, please visit benchworks.com or call 800-536-4670.

About PM360

PM360 is the premier, must-read magazine for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device industries. Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharmaceutical marketing professionals to succeed in the complex and highly regulated healthcare environment.

The journal’s targeted and insightful editorial focuses on issues that directly impact critical decision making, including: Planning and implementation of cutting-edge strategies, trends, the latest technological advances, branding/marketing, advertising/promotion, patient/professional education, sales, market research, PR, and leadership. Additionally, the “360” in the title signifies the span of this critical, how-to info with personal and career insights for an enjoyable and thought-provoking read.

By providing the full circle of enriching content, PM360 is truly an indispensable tool for busy and productive marketing professionals to stay at the top of their game.

Share article on social media or email: